AM-679
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 573765

CAS#: 335160-91-3

Description: AM-679 is a 5-lipoxygenase-activating protein (FLAP) inhibitor.

Chemical Structure

img
AM-679
CAS# 335160-91-3
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 573765
Name: AM-679
CAS#: 335160-91-3
Chemical Formula: C20H20INO
Exact Mass: 417.06
Molecular Weight: 417.290
Elemental Analysis: C, 57.57; H, 4.83; I, 30.41; N, 3.36; O, 3.83

Price and Availability

Size Price Availability Quantity
5mg USD 240
10mg USD 400
25mg USD 705
Bulk inquiry

Synonym: AM-679, AM679, AM 679

IUPAC/Chemical Name: 1-Pentyl-3-(2-iodobenzoyl)indole

InChi Key: GAJBHYUAJOTAEW-UHFFFAOYSA-N

InChi Code: 1S/C20H20INO/c1-2-3-8-13-22-14-17(15-9-5-7-12-19(15)22)20(23)16-10-4-6-11-18(16)21/h4-7,9-12,14H,2-3,8,13H2,1H3

SMILES Code: CCCCCn1cc(c2c1cccc2)C(=O)c3ccccc3I

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: AM679 is a potent, selective 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 2 nM in a human FLAP membrane binding assay.
In vitro activity: ll of the biaryl compounds 34 to 39 (AM679) showed excellent in vitro inhibition against FLAP. Of particular note was compound 39 with an excellent hWB IC50 potency of 154 nM. This compound also showed an improved CYP inhibition profile (IC50 3A4 = 16.7 μM, 2C9 = 3.7 μM, 2D6 >30 μM), no time dependent inhibition against CYP3A4 (0.003 min−1 vs 0.057 min−1 for troleandomycin control @ 10 μM) and no CYP3A4 induction. The pharmacokinetic properties of 39 had also significantly improved over the chlorobenzyl derivative 20, showing reasonable bioavailability, low clearance and improved AUC (10 mg/kg sodium carboxylate salt in rat po F = 29%, Cl = 11 mL/min/kg, Cmax = 1.6 μM, AUC = 4.6 h μg/mL, T½ = 6.8 h). Reference: Bioorg Med Chem Lett. 2010 Jan 1;20(1):213-7. https://pubmed.ncbi.nlm.nih.gov/19914828/
In vivo activity: To determine if a FLAP LT synthesis inhibitor can ameliorate eye inflammation following RSV infection, this study treated one eye of drug-treated mice with 60 ng AM679 in 2 μl sterile saline (or one eye of control mice with 2 μl sterile saline only) 40 min after inoculation with 106 PFU RSV and then every day afterward for 13 more days. The RSV-infected eyes from control mice showed ocular inflammation, mucus, and conjunctivitis that peaked 6 to 8 days after infection and largely resolved by 14 days (Fig. 3). The FLAP inhibitor AM679-treated mouse eyes showed significant protection from RSV-induced pathology as early as 2 days continuing to 14 days postinfection. At 6 to 8 days the FLAP inhibitor-treated eyes showed greater then 70% reduction in total pathological scores. Representative eyes from both control and AM679-treated mice through days 2 to 6 clearly demonstrate the reduced inflammation and mucus in the drug-treated animals (Fig. 3). Reference: Clin Vaccine Immunol. 2009 Nov; 16(11): 1654–1659. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2772391/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 57.0 136.60
DMF 10.0 23.96
Ethanol 10.0 23.96

Preparing Stock Solutions

The following data is based on the product molecular weight 417.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Stock N, Baccei C, Bain G, Broadhead A, Chapman C, Darlington J, King C, Lee C, Li Y, Lorrain DS, Prodanovich P, Rong H, Santini A, Zunic J, Evans JF, Hutchinson JH, Prasit P. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):213-7. doi: 10.1016/j.bmcl.2009.10.131. Epub 2009 Oct 31. PMID: 19914828. 2. Musiyenko A, Correa L, Stock N, Hutchinson JH, Lorrain DS, Bain G, Evans JF, Barik S. A novel 5-lipoxygenase-activating protein inhibitor, AM679, reduces inflammation in the respiratory syncytial virus-infected mouse eye. Clin Vaccine Immunol. 2009 Nov;16(11):1654-9. doi: 10.1128/CVI.00220-09. Epub 2009 Sep 16. PMID: 19759251; PMCID: PMC2772391.
In vitro protocol: 1. Stock N, Baccei C, Bain G, Broadhead A, Chapman C, Darlington J, King C, Lee C, Li Y, Lorrain DS, Prodanovich P, Rong H, Santini A, Zunic J, Evans JF, Hutchinson JH, Prasit P. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):213-7. doi: 10.1016/j.bmcl.2009.10.131. Epub 2009 Oct 31. PMID: 19914828.
In vivo protocol: 1. Stock N, Baccei C, Bain G, Broadhead A, Chapman C, Darlington J, King C, Lee C, Li Y, Lorrain DS, Prodanovich P, Rong H, Santini A, Zunic J, Evans JF, Hutchinson JH, Prasit P. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):213-7. doi: 10.1016/j.bmcl.2009.10.131. Epub 2009 Oct 31. PMID: 19914828. 2. Musiyenko A, Correa L, Stock N, Hutchinson JH, Lorrain DS, Bain G, Evans JF, Barik S. A novel 5-lipoxygenase-activating protein inhibitor, AM679, reduces inflammation in the respiratory syncytial virus-infected mouse eye. Clin Vaccine Immunol. 2009 Nov;16(11):1654-9. doi: 10.1128/CVI.00220-09. Epub 2009 Sep 16. PMID: 19759251; PMCID: PMC2772391.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Stock N, Baccei C, Bain G, Broadhead A, Chapman C, Darlington J, King C, Lee C, Li Y, Lorrain DS, Prodanovich P, Rong H, Santini A, Zunic J, Evans JF, Hutchinson JH, Prasit P. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5 -methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):213-7. doi: 10.1016/j.bmcl.2009.10.131. Epub 2009 Oct 31. PubMed PMID: 19914828.

2: Musiyenko A, Correa L, Stock N, Hutchinson JH, Lorrain DS, Bain G, Evans JF, Barik S. A novel 5-lipoxygenase-activating protein inhibitor, AM679, reduces inflammation in the respiratory syncytial virus-infected mouse eye. Clin Vaccine Immunol. 2009 Nov;16(11):1654-9. doi: 10.1128/CVI.00220-09. Epub 2009 Sep 16. PubMed PMID: 19759251; PubMed Central PMCID: PMC2772391.